Suppressor of Cytokine Signaling 3 (SOCS3) is not an independent biomarker of colorectal adenoma risk by Galanko, Joseph et al.
Hamilton et al. BMC Research Notes 2010, 3:144
http://www.biomedcentral.com/1756-0500/3/144
Open AccessSHORT REPORTShort ReportSuppressor of cytokine signaling 3 (SOCS3) is not 
an independent biomarker of colorectal adenoma 
risk
Kathryn E Hamilton1, P Kay Lund1, Joseph A Galanko2, Robert S Sandler2 and Temitope O Keku*2
Abstract
Background: Inflammation and its associated pathologies are increasingly suggested as risk factors for colorectal 
cancer (CRC) development. Previous research from our group has shown that increased levels of circulating, pro-
inflammatory cytokines IL-6 and TNFα promote colorectal adenoma risk. Emerging data in mice and humans suggest 
that Suppressor of Cytokine Signaling 3 (SOCS3) may act as a tumor suppressor in the intestine, and decreased SOCS3 
expression may promote CRC. As SOCS3 has been shown to inhibit the actions of IL-6 and TNFα in the intestine, we 
hypothesized that decreased SOCS3 expression in normal mucosa may predispose to adenomas and thus increase risk 
for CRC.
Findings: We examined SOCS3 mRNA levels in normal mucosa biopsies of 322 screening colonoscopy patients (93 
with adenoma and 229 without adenoma) using real-time qRT-PCR. Logistic regression analysis was used to generate 
odds ratios (OR) and 95% confidence intervals to determine if low SOCS3 expression was associated with adenoma 
status. Median SOCS3 values did not differ between patients with or without adenoma. Logistic regression analysis 
showed no association (unadjusted or adjusted for age and sex) between SOCS3 and colorectal adenomas.
Conclusions: Low SOCS3 mRNA expression is not an independent biomarker of colorectal adenoma risk in the normal 
mucosa. SOCS3 silencing likely occurs later in CRC progression.
Introduction
Recent evidence in mice and humans suggest that the
anti-inflammatory protein Suppressor of Cytokine Sig-
naling 3 (SOCS3) may act as a tumor suppressor in the
colon [1,2]. Specific silencing of SOCS3 expression in
intestinal epithelial cells (IEC) increased tumor load in
the azoxymethane/dextran sodium sulfate (AOM/DSS)
mouse model of inflammation-associated CRC [1]. Fur-
thermore, SOCS3 expression is low or silenced by pro-
moter hyper-methylation in other cancers, including
lung, liver, and squamous cell carcinoma [3-5].
Prior studies from our group demonstrated that
increased systemic levels of pro-inflammatory cytokines
IL-6 and TNFα correlate with risk of colorectal adenoma
[6]. SOCS3 has been shown to limit the actions of both of
these cytokines as well as their downstream targets
STAT3 and NFκB, which are frequently activated in
humans and mouse models of CRC [2,7-12]. Based on
these studies, we investigated SOCS3 mRNA expression
in the normal mucosa of patients undergoing routine
screening colonoscopy to determine if low SOCS3 pre-
disposes to adenoma and could thus be considered an
early biomarker of CRC risk.
Materials and methods
Study Population and Data Collection
All eligible subjects provided written, informed consent.
Consenting participants were enrolled in Diet and Health
Study IV at University of North Carolina Hospitals as
previously described [13]. Briefly, subjects undergoing
routine colonoscopy provided rectal biopsies and blood
samples for the study. Subjects also consented to follow-
up interview to collect diet and lifestyle information.
High quality RNA from 322 subjects (93 with adenoma,
229 without adenoma) with complete information on
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(WHR), family history and non-steroidal anti-inflamma-
tory drug (NSAID) use was assayed for SOCS3. Patients
in the adenoma group were defined as having one or
more adenomas by the study pathologist based on stan-
dard criteria. The study was approved by the University
of North Carolina School of Medicine Institutional
Review Board.
RNA Extraction and Real-Time qRT-PCR
RNA from four pooled, normal colon biopsies per subject
was extracted using Qiagen's RNeasy kit (Valencia, CA)
and reverse transcribed with AMV-Reverse Tran-
scriptase (Promega) as previously described [13].
SOCS3 mRNA abundance was determined using the
ABI Prism 7900 HT (Applied Biosystems, Foster City,
CA) and Platinum Quantitative PCR SuperMix-UDG
(Invitrogen, Carlsbad, CA). Human SOCS3
(NM_003955.3) was quantified using Applied Biosystem
primer/probe set targeting exon 2. The housekeeping
gene hydroxymethylbilane synthase (HMBS,
NM_000190.3) was chosen as a low-abundance, invariant
control. Standard curves for each primer/probe set were
generated using gel-isolated, sequence-confirmed PCR
products. Cycling included initial denaturation at 95°C
for 5 minutes followed by 45 cycles of 95°C denaturation
for 15 seconds and 60°C annealing for 45 seconds.
Threshold cycles analysis was performed using Applied
Biosystem SDS v2.2.2 software and values are expressed
as copy number relative to HMBS. All PCR runs included
standards and inter-run calibrator controls (pooled sam-
ple cDNA), as well as non-reverse transcribed (no-RT)
and water controls. Samples were run in triplicate.
Statistical Analysis
Means and standard errors were generated for continu-
ous variables, and frequencies and percentages were gen-
erated for categorical variables. T-tests and Mann-
Whitney tests were used to compare cases with controls
on continuous variables. SOCS3 values were log-trans-
formed to normalize the distribution. Chi-Square tests
were used to compare cases and controls on categorical
variables. Logistic regression was used to test for an asso-
ciation between case/control status and SOCS3. Levels of
SOCS3 were categorized into tertiles based on control
values. Age, race, sex, WHR, NSAIDS, IL-6, TNFα, and
family history were assessed as potential confounders of
SOCS3-adenoma association. Each variable was put into
a model separately with SOCS3, and if one of the two
dummy variables for SOCS3 changed by at least 15%
compared to when only SOCS3 was in the model, then
that co-variable passed the first stage for being a con-
founder. All such variables were then entered into a
model with SOCS3 and a backwards, stepwise regression
was done with the SOCS3 variable being forced into the
model. Only age and sex met these criteria for confound-
ing and thus they were included in the final model.
Results
Descriptive characteristics of the population in the
SOCS3-adenoma study are shown in Table 1. Consistent
with results from our prior reports for the study popula-
tion, subjects with adenomas were older, more likely to be
male, had higher waist-hip ratios and increased plasma
IL-6 [6,13]. There was no difference in median SOCS3
between individuals with or without adenoma.
Table 1: Descriptive Characteristics of Study Participants
Variable Case (n = 93) Control (n = 229) p-value *
Age median (1st, 3rd quartile)** 58 (51, 56) 55 (50, 63) 0.03
Race-White N (%)† 73 (78) 177 (77) 0.88
Sex-Male N (%) 51 (55) 85 (37) 0.004
WHR median (1st, 3rd quartile) 0.922 (0.854, 1.000) 0.888 (0.804, 979) 0.04
Family History of CRC - N (%) 16 (20) 31 (15) 0.37
Plasma IL-6 median (1st, 3rd quartile) 0.21 (0.00, 0.56) 0.07 (0.00, 0.41) 0.01
Plasma TNFα median (1st, 3rd quartile) 1.93 (1.44, 2.74) 1.75 (1.30, 2.44) 0.14
Plasma CRP median (1st, 3rd quartile) 3,959 (1,934, 14,278) 7,239 (2,294, 16,728) 0.14
Tissue SOCS3 median (1st, 3rd quartile) 3.09 (2.33, 3.77) 3.09 (2.35, 3.80) 0.77
* P-values are from Fishers Exact Test for categorical variables and Mann-Whitney test to compare medians for continuous variables.
** Standard error (se); Waist Hip Ratio (WHR); Suppressor of Cytokine Signaling 3 (SOCS3)
† Percentages within columns
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adenoma, odds ratios and 95% confidence intervals were
generated using logistic regression analysis (Table 2).
There was no difference in odds ratios in subjects in the
lower tertiles of SOCS3 values, indicating that low levels
of local SOCS3 expression do not associate with adenoma
risk.
Discussion
Identifying local factors that predispose patients to early,
pre-cancerous lesions may make it possible to stratify
screening based on risk, but risk factors that occur early
in CRC development are not well defined. Our group has
shown that patients with adenoma have reduced apopto-
sis in their normal mucosa, demonstrating a field effect
that predisposes the individual to a higher risk of devel-
oping precancerous adenomas [14,15]. We hypothesized
that SOCS3 might be a good biomarker of colorectal neo-
plasia risk, but contrary to expectation the study was neg-
ative.
Patients with inflammatory bowel diseases (Crohn's
disease or ulcerative colitis) have an increased risk of
developing CRC, which is associated with the degree and
duration of intestinal inflammation (reviewed in [16]). In
addition, recent data suggest that individuals with
chronic, low levels of inflammation (such as increased
circulating IL-6 and TNFα) have increased odds of having
adenoma and thus increased CRC risk [6]. SOCS3 is an
anti-inflammatory protein that limits IL-6 induction of
STAT3, as well as TNFα induction of NFκB. IEC-specific
silencing of SOCS3 leads to a dramatic increase in tumor
load in a mouse model of inflammation-associated CRC
[1]. Furthermore, recent studies show that STAT3 activa-
tion is increased, and SOCS3 is silenced in tumors of
patients with ulcerative colitis-associated and sporadic
CRC [2,17]. The current study tested the hypothesis that
patients with adenoma may have lower SOCS3 in the
normal mucosa than patients without adenoma, thus
contributing to a permissive environment for aberrant
growth. However, our study found that low or silenced
SOCS3 expression does not occur in the normal mucosa
of patients with colorectal adenoma.
One potential limitation of the study is possible effect
of standard bowel preparation on SOCS3 expression.
While we have not directly tested this for SOCS3, similar
studies of other genes have shown that there is no signifi-
cant change in mucosal gene expression in patients using
bisacodyl or polyethylene glycol bowel preparations [18].
Another possible limitation is that SOCS3 mRNA levels
do not reflect changes in SOCS3 phosphorylation, which
leads to its targeting for proteasomal degradation [19].
However, other studies show that SOCS3 is silenced by
DNA hyper-methylation in CRC tumors [2], indicating
that evaluating changes in gene expression is an appropri-
ate measure of SOCS3 in this study. Finally, while our
results could indicate that SOCS3 is more important in
the underlying pathogenesis of inflammation-associated
rather than sporadic CRC, recent studies comparing
SOCS3 expression in both ulcerative colitis-associated
and sporadic tumors found that SOCS3 was decreased
and there was no significant difference between the two
groups for SOCS3 [2]. Taken together with these studies,
we conclude that SOCS3 silencing occurs later in the pro-
gression from adenoma to adenocarcinoma, and is not an
independent, early biomarker of CRC risk in the normal
mucosa.
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Table 2: Adjusted Association Between Local SOCS3 Levels and Adenoma
Tissue SOCS3 Case/Control* OR (95% CI)†
Tertile 3 (36.4-180.7)‡ 28/69 1.0 (Reference)
Tertile 2 (13.8-36.4) 27/72 0.9 (0.5, 1.7)
Tertile 1 (0.6-13.8) 29/69 1.0 (0.5, 1.8)
*Adjusted for age and sex
†Odds ratio (OR) and 95% confidence interval (CI); odds of having colorectal adenomas
‡Tertile cut-offs based on distribution of SOCS3 among control subjects; tertile 3 was used as reference
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